ArticleMicrobiome2026
Agarose oligosaccharides balance intestinal stem cell homeostasis in aging D. melanogaster by regulating the Acetobacter persici-acetic acid-JAK/STAT signaling axis.
Article in Microbiome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiota metabolites in inflammatory bowel disease: advances in mechanistic insights.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundIntestinal aging manifests as the decline in gut function and structure, affecting nutrient absorption and overall health. Agarose oligosaccharides (AOS) exhibit considerable anti-aging effects, but their mechanism of action remains unclear.
resultsHere, aging male Drosophila melanogaster (D. melanogaster) were employed to evaluate the effects of AOS on the proliferation and differentiation of intestinal stem cell (ISC) and its underlying mechanism. Our findings revealed that supplementation with AOS significantly extended mean and maximum lifespan, reduced oxidative stress, and alleviated intestinal epithelial barrier dysfunction. Notably, AOS supplementation reduced the mean fluorescence intensity of esg⁺ cells and enteroblasts (EB), leading to an improvement in ISC homeostasis, with potential mechanisms associated with activation of the PERK and JAK/STAT signaling pathways, as demonstrated by RNA interference. Integrated 16S rRNA sequencing, strain isolation, and short-chain fatty acids (SCFAs) analysis revealed that AOS was beneficial for intestinal microflora and its metabolites, evidenced by the significant increase in Acetobacter persici and acetic acid contents. Importantly, further experiments demonstrated that Acetobacter persici and acetic acid treatment could significantly decrease the esg⁺ ISC count and downregulate the expression levels of PERK, STAT, and Hsp70Bbb, suggesting that AOS can increase production of Acetobacter persici and its metabolite acetic acid, thereby modulating JAK/STAT signaling to improve ISC steady-state.
conclusionsThe homeostasis of ISC in aging D. melanogaster is balanced by AOS via the acetic acid-JAK/STAT axis mediated by Acetobacter persici. This axis counters age-related ISC dysregulation by balancing proliferative signals with redox homeostasis, positioning AOS as a microbiota-targeted intervention for age-associated intestinal decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.